Lucence at #ISLB2022

Dare to Compare
October 20-22, 2022

scroll-arrow

From the CEO

Friends and colleagues,

Please join us at the 4th Annual Congress of Liquid Biopsy, organised by the International Society of Liquid Biopsy, from October 20-22 2022. On this page you’ll find information on our latest news and updates we will be sharing.

At ISLB2022, we’re excited to share the excellent results of LiquidHALLMARK’s comparison study, and more. Our team will be present and we hope you will get in touch. Sign up here to make sure you receive the latest Lucence news and updates. For questions or assistance, do not hesitate to reach out to us at [email protected]

We’re looking forward to seeing you in person.

Gratefully,

Min Han Tan

news-image1 news-image2

News

Lucence Showcases Promising Comparison Study Results at 4th Annual Congress of Liquid Biopsy.

Read Release Here

Poster Presentations
and Abstracts for #ISLB2022

21 October 2022
Comparison between LiquidHALLMARK and an FDA-Approved Assay for G9 detection in patients with at least one tissue-positive G9 biomarker.

Authors:

Richa Dawar 1, Jennifer Carney 2, James Orsini Jr. 3, Katherine Scilla 4,  Gilberto Lopes 1, Min-Han Tan 5, Yew Oo Tan 6, Tan Min Chin 7, Chee Keong Toh 8, Boon Cher Goh 9, Jens Samol 10,11.

 

1 University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, USA; 2 Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, USA; 3 New Jersey Cancer Care, Belleville, New Jersey, USA; 4 University of Maryland School of Medicine, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA; 5 Lucence Health, Palo Alto, California, USA; 6 Icon Cancer Centre Farrer Park, Singapore; 7 Parkway Cancer Centre, Singapore; 8 Curie Oncology, Singapore; 9 National University Hospital, Singapore; 10 Medical Oncology Tan Tock Seng Hospital, Singapore; 11 Johns Hopkins University, Baltimore, USA

 

Abstract PP.03: View Here

Poster number: Read Here

Get Updates

Sign up for the latest news and updates about Lucence at #ISLB2022. For questions, email us at [email protected].